Opinions The Panic-Proof Portfolio (Stockchase Research)
Harvest Big Pharma Split Corp.PRM.TOTOP PICKJul 07, 2026
Stock price when the opinion was issued
As of Aug 14, 2026. Market Open.
You might be interested:
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentWe reiterate PRM, a portfolio of the 10 world's largest pharma and biotech companies, as a TOP PICK. The fund manages a balance of underlying shares with dividends and options to create an enhanced yield for investors, which presently yields over 8%. We recommend trailing up the stop (from $10) to $13, looking to achieve $18 -- upside over 18%. Yield 8.2%
(Analysts’ price target is $32.78)Premium contentPRM hold a portfolio of 10 of the world's largest pharmaceutical and biotechnology companies. The fund managers use a balance of the underlying shares with dividends and options to create an enhanced yield. We like that recent earnings show healthy and growing cash reserves. The shares held their value during the severe market downturns in 2018 and 2022 -- actually increasing 11% in each -- providing good market volatility protection. We recommend setting a stop-loss at $10.00, looking to achieve $15.00 -- upside potential of 18%. Yield 7.2%
We again reiterate PRM, holder of a basket of top pharma companies with enhanced distributions as a TOP PICK. Recently announced distributions provide a strong yield and the pharma sector as a whole is performing consistently. We continue to recommend a stop at $13, looking to achieve $17 -- upside potential of 17%. Yield 8.6%